Skip to main content
Brian J. Mickey
No Rating Available
(Learn About Our Rating System)

Brian J. Mickey, MD, PhD

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Mental Health Institute

501 Chipeta Way
Salt Lake City , UT 84108

Brian J. Mickey, MD, PhD is Professor of Psychiatry. He studied physics and biology at the University of Washington, Seattle, then completed his MD and PhD in Neuroscience at the University of Michigan, Ann Arbor. After psychiatry residency and postdoctoral fellowship at the Molecular & Behavioral Neuroscience Institute, he joined the faculty at the University of Michigan. In 2015, he moved to the University of Utah, where he is a faculty member in Psychiatry, Neuroscience, Biomedical Engineering, and Anesthesiology.

Dr. Mickey is board-certified in Psychiatry. His clinical focus is treatment-resistant mood disorders. He provides pharmacologic treatments and brain stimulation interventions in the Treatment Resistant Mood Disorders Clinic at the Huntsman Mental Health Institute.

The overall objectives of Dr. Mickey's lab are to understand how limbic and prefrontal brain circuits give rise to psychiatric problems such as depression, anxiety, and addiction, and to develop new circuit-targeted interventions that return the brain to a healthy state.

Lab web site

Specialties

Board Certification

American Board of Psychiatry & Neurology (Psychiatry)

Brian J. Mickey, MD, PhD is Professor of Psychiatry. He studied physics and biology at the University of Washington, Seattle, then completed his MD and PhD in Neuroscience at the University of Michigan, Ann Arbor. After psychiatry residency and postdoctoral fellowship at the Molecular & Behavioral Neuroscience Institute, he joined the faculty at the University of Michigan. In 2015, he moved to the University of Utah, where he is a faculty member in Psychiatry, Neuroscience, Biomedical Engineering, and Anesthesiology.

Dr. Mickey is board-certified in Psychiatry. His clinical focus is treatment-resistant mood disorders. He provides pharmacologic treatments and brain stimulation interventions in the Treatment Resistant Mood Disorders Clinic at the Huntsman Mental Health Institute.

The overall objectives of Dr. Mickey's lab are to understand how limbic and prefrontal brain circuits give rise to psychiatric problems such as depression, anxiety, and addiction, and to develop new circuit-targeted interventions that return the brain to a healthy state.

Lab web site

Board Certification and Academic Information

Academic Departments Psychiatry -Professor (Clinical)
Anesthesiology -Adjunct Associate Professor
Academic Divisions Adult Psychiatry
Board Certification
American Board of Psychiatry & Neurology (Psychiatry)

Education history

Undergraduate Physics, Biology, dual major - University of Washington B.S.
Professional Medical Medicine, Neuroscience - University of Michigan Medical School M.D., Ph.D.
Residency Psychiatry - University of Michigan Health System Resident
Research Fellow University of Michigan, Molecular & Behavioral Neuroscience Institute Research Fellow

Selected Publications

Journal Article

  1. Richards JR, Pace BD, Lynch A, Weber AN, Vaidya J, Jawish R, Jones KG, Mickey BJ, Carnahan RM, and Trapp N (2025). Dual-target theta burst rTMS in the treatment of methamphetamine use disorder: An open-label pilot clinical trial randomized by target sequence. Brain stimulation, in press,
  2. Jawish R, Shangraw K, Charles JE, Eddington B, Worden J, Tak C, Mickey BJ, Gordon AJ, Smid M (2025). Interest in Transcranial Magnetic Stimulation (TMS) Therapy for Treatment of Depression and Substance Use Disorder Among Peripartum Individuals. Journal of addiction medicine, in press,
  3. Franklin, Achtyes, Altinay, Bailey, Bhati, Carr, Conroy, Husain, Khurshid, Lencz, McDonald, Mickey BJ, Murrough, Nestor, Nickl-Jockschat, Nikayin, Reeves, Reti, Selek, Sanacora, Trapp, Viswanath, Wright, Sullivan, Zandi, Potas (2025). Genetics of Response to ECT, TMS, ketamine and esketamine. American journal of human genetics, in press,
  4. Conway CR, Aaronson ST, Sackeim HA, George MS, Zajecka J, Bunker MT, Duffy W, Stedman M, Riva-Posse P, Allen RM, Quevedo J, Berger M, Alva G, Malik MA, Dunner DL, Cichowicz I, Banov M, Manu L, Nahas Z, Macaluso M, Mickey BJ, Sheline Y, Kriedt CL, Lee YL, Gordon C, Shy O, Tran Q, Yates L, Rush A (2025). Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. Brain stimulation, 18(3), 676-689.
  5. Rush AJ, Conway CR, Aaronson ST, George MS, Riva-Posse P, Dunner DL, Zajecka J, Bunker MT, Quevedo J, Allen RM, Alva G, Luing H, Nahas Z, Manu L, Bennett JI, Mickey BJ, Becker J, Sheline Y, Cusin C, Murrough JW, Reeves K, Rosenquist PB, Lee YL, Majewski S, Way J, Olin B, Sackeim H (2025). Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. Brain stimulation, 18(3), 690-700.
  6. Trapp NT, Purgianto A, Taylor JJ, Singh MK, Oberman LM, Mickey BJ, Youssef NA, Solzbacher D, Zebley B, Cabrera LY, Conroy S, Cristancho M, Richards JR, Flood MJ, Barbour T, Blumberger DM, Taylor SF, Feifel D, Reti IM, McClintock SM, Lisanby SH, Husain MM, National Network of Depression Centers Neuromodulation Task Grou (2025). Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology. Clinical neurophysiology, 170, 206-233.
  7. Riis TS, Feldman DA, Kwon SS, Vonesh LC, Koppelmans V, Brown JR, Solzbacher D, Kubanek J, Mickey B (2025). Noninvasive Modulation of the Subcallosal Cingulate and Depression With Focused Ultrasonic Waves. Biological psychiatry, 97(8), 825-834.
  8. Feldman DA, Jones KG, Vonesh LC, Jacobs R, Hoffman N, Lybbert C, Huang J, Kuck K, Odell D, Tadler SC, Mickey B (2025). Immediate effects of propofol on mood: a randomized comparison of two doses in a cohort with depression. Psychopharmacology, 242(3), 481-495.
  9. Thurston MD, Ericksen LC, Jacobson MM, Bustamante A, Koppelmans V, Mickey BJ, Love T (2025). Oxytocin differentially modulates reward system responses to social and non-social incentives. Psychopharmacology, 242(3), 449-460.
  10. Franklin CE, Achtyes E, Altinay M, Bailey K, Bhati MT, Carr BR, Conroy SK, Husain MM, Khurshid KA, Lencz T, McDonald WM, Mickey BJ, Murrough J, Nestor S, Nickl-Jockschat T, Nikayin S, Reeves K, Reti IM, Selek S, Sanacora G, Trapp NT, Viswanath B, Wright JH, Sullivan P, Zandi PP, Potash J (2025). The genetics of severe depression. Molecular psychiatry, 30(3), 1117-1126.
  11. Douka I, Ruitenberg MFL, Weischedel K, Phouthavongsay C, Weisenbach SL, Van Der Geest J, Mickey BJ, Koppelmans¿ (2025). Cognitive and Motor Disturbances in Depression: Insights from Comprehensive Behavioral Assessments. Frontiers in psychiatry, in press,
  12. Polcyn R, Arbon J, Hansen A, Gaudin A, Mickey B (2025). Ethical Considerations and Current Attitudes Towards Neuromodulation in Forensic Psychiatry. The journal of the American Academy of Psychiatry and the Law, in press,
  13. Carmona Osorio P, Ruitenberg MFL, Weischedel K, Douka I, Phouthavongsay CA, Weisenbach SL, Van Der Geest J, Mickey BJ, Koppelmans¿ (2025). Visuomotor Adaptation and Savings Are Preserved in Individuals With Depression. Journal of motor learning and development, in press,
  14. Tsunoda K, Webb T, Lybbert C, Wilson M, Mickey B, Kubanek (2025). Noninvasive suppression of responses to threat using focused ultrasonic waves. The Journal of neuroscience, in press,
  15. Jawish R, Tawfik AG, Mickey B, Gordon A, Silver R, Smid MC, Tak (2025). Cost-Effectiveness of Transcranial Magnetic Stimulation Compared to Combination Injectable Naltrexone and Bupropion for the Treatment of Methamphetamine Use Disorder During Pregnancy. The journal of mental health policy and economics, in press,
  16. Riis TS, Feldman DA, Mickey BJ, Kubanek (2024). Controlled noninvasive modulation of deep brain regions in humans. Communications engineering, 3, 13.
  17. Riis T, Feldman D, Losser A, Mickey B, Kubanek (2024). Device for Multifocal Delivery of Ultrasound Into Deep Brain Regions in Humans. IEEE transactions on bio-medical engineering, 71(2), 660-668.
  18. Provenza NR, Reddy S, Allam AK, Rajesh SV, Diab N, Reyes G, Caston RM, Katlowitz KA, Gandhi AD, Bechtold RA, Dang HQ, Najera RA, Giridharan N, Kabotyanski KE, Momin F, Hasen M, Banks GP, Mickey BJ, Kious BM, Shofty B, Hayden BY, Herron JA, Storch EA, Patel AB, Goodman WK, Sheth S (2024). Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder. Nature medicine, 30(10), 3004-3014.
  19. Conway CR, Aaronson ST, Sackeim HA, Duffy W, Stedman M, Quevedo J, Allen RM, Riva-Posse P, Berger MA, Alva G, Malik MA, Dunner DL, Cichowicz I, Luing H, Zajecka J, Nahas Z, Mickey BJ, Kablinger AS, Kriedt CL, Bunker MT, Lee YL, Shy O, Majewski S, Olin B, Tran Q, Rush A (2024). Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report. Brain stimulation, 17(2), 448-459.
  20. Nunez NA, Joseph B, Kumar R, Douka I, Miola A, Prokop LJ, Mickey BJ, Singh (2023). An Update on the Efficacy of Single and Serial Intravenous Ketamine Infusions and Esketamine for Bipolar Depression: A Systematic Review and Meta-Analysis. Brain sciences, 13(12),
  21. Lybbert C, Huang J, Jones KG, Mickey BJ, Tadler S, Odell D, Stanford J, Kuck (2023). Clinical validation of an adapted Eleveld Model for high-dose propofol treatments for depression. Journal of clinical monitoring and computing, 37(5), 1369-1377.
  22. Shah SB, Peddada TN, Song C, Mensah M, Sung H, Yavi M, Yuan P, Zarate CA Jr, Mickey BJ, Burmeister M, Akula N, McMahon F (2023). Exome-wide association study of treatment-resistant depression suggests novel treatment targets. Scientific reports, 13(1), 12467.
  23. Jones KG, Lybbert C, Euler MJ, Huang J, Lunt S, Richards SV, Jessop JE, Larson A, Odell DH, Kuck K, Tadler SC, Mickey B (2023). Diversity of electroencephalographic patterns during propofol-induced burst suppression. Frontiers in systems neuroscience, 17, 1172856.
  24. Silcox JW, Mickey B, Payne B (2023). Disruption to left inferior frontal cortex modulates semantic prediction effects in reading and subsequent memory: Evidence from simultaneous TMS-EEG. Psychophysiology, 60(9), e14312.
  25. Baker AK, Ericksen LC, Koppelmans V, Mickey BJ, Martucci KT, Zubieta JK, Love T (2022). Altered Reward Processing and Sex Differences in Chronic Pain. Frontiers in neuroscience, 16, 889849.
  26. Oka F, Weischedel K, Bakian A, Mickey B (2022). Treatment-Resistant Mood Disorders in LGBTQ People: A Retrospective Study of Clinical Features and Response to Electroconvulsive Therapy. The Journal of clinical psychiatry, 83(4),
  27. Langenecker SA, Westlund Schreiner M, Thomas LR, Bessette KL, DelDonno SR, Jenkins LM, Easter RE, Stange JP, Pocius SL, Dillahunt A, Love TM, Phan KL, Koppelmans V, Paulus M, Lindquist MA, Caffo B, Mickey BJ, Welsh R (2022). Using Network Parcels and Resting-State Networks to Estimate Correlates of Mood Disorder and Related Research Domain Criteria Constructs of Reward Responsiveness and Inhibitory Control. Biological psychiatry. Cognitive neuroscience and neuroimaging, 7(1), 76-84.
  28. Warthen KG, Welsh RC, Sanford B, Koppelmans V, Burmeister M, Mickey B (2021). Neuropeptide Y Variation Is Associated With Altered Static and Dynamic Functional Connectivity of the Salience Network. Frontiers in systems neuroscience, 15, 629488.
  29. Mickey BJ, Ginsburg Y, Jensen E, Maixner D (2021). Distinct predictors of short- versus long-term depression outcomes following electroconvulsive therapy. Journal of psychiatric research, 145, 159-166.
  30. Lex H, Nevers SW, Jensen EL, Ginsburg Y, Maixner DF, Mickey B (2021). Long-term quality of life in treatment-resistant depression after electroconvulsive therapy. Journal of affective disorders, 291, 135-139.
  31. Pierson MD, Mickey BJ, Gilley LB, Weeks HR II (2021). Outcomes of Youth Treated With Electroconvulsive Therapy: A Retrospective Cohort Study. The Journal of clinical psychiatry, 82(2),
  32. Hsu DT, Sankar A, Malik MA, Langenecker SA, Mickey BJ, Love T (2020). Common neural responses to romantic rejection and acceptance in healthy adults. Social neuroscience, 15(5), 571-583.
  33. Warthen KG, Boyse-Peacor A, Jones KG, Sanford B, Love TM, Mickey B (2020). Sex differences in the human reward system: convergent behavioral, autonomic and neural evidence. Social cognitive and affective neuroscience, 15(7), 789-801.
  34. Soda T, McLoughlin DM, Clark SR, Oltedal L, Kessler U, Haavik J, Bousman C, Smith DJ, Bioque M, Clements CC, Loo C, Vila-Rodriguez F, Minelli A, Mickey BJ, Milev R, Docherty AR, Langan Martin J, Achtyes ED, Arolt V, Redlich R, Dannlowski U, Cardoner N, Clare E, Craddock N, Di Florio A, Dmitrzak-Weglarz M, Forty L, Gordon-Smith K, Husain M, Ingram WM, Jones L, Jones I, Juruena M, Kirov G, Landén M, Müller DJ, Nordensköld A, Pålsson E, Paul M, Permoda A, Pliszka B, Rea J, Schubert KO, Sonnen JA, Soria V, Stageman W, Takamiya A, Urretavizacaya M, Watson S, Zavorotny M, Young AH, Vieta E, Rybakowski JK, Gennarelli M, Zandi PP, Sullivan PF, Baune BT (2019). International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). Eur Arch Psychiatry Clin Neurosci, 270(7), 921-932.
  35. DelDonno SR, Mickey BJ, Pruitt PJ, Stange JP, Hsu DT, Weldon AL, Zubieta JK, Langenecker S (2019). Influence of childhood adversity, approach motivation traits, and depression on individual differences in brain activation during reward anticipation. Biological psychology, 146, 107709.
  36. Warthen KG, Sanford B, Walker K, Jones KG, Angstadt M, Sripada C, Goldman D, Zubieta JK, Welsh RC, Burmeister M, Mickey B (2019). Neuropeptide Y and representation of salience in human nucleus accumbens. Neuropsychopharmacology, 44(3), 495-502.
  37. Lex H, Ginsburg Y, Sitzmann AF, Grayhack C, Maixner DF, Mickey B (2019). Quality of life across domains among individuals with treatment-resistant depression. Journal of affective disorders, 243, 401-407.
  38. Kang GE, Mickey BJ, Krembs BS, McInnis MG, Gross M (2019). The effect of mood phases on balance control in bipolar disorder. Journal of biomechanics, 82, 266-270.
  39. Langenecker SA, Klumpp H, Peters AT, Crane NA, DelDonno SR, Bessette KL, Ajilore O, Leow A, Shankman SA, Walker SJ, Ransom MT, Hsu DT, Phan KL, Zubieta JK, Mickey BJ, Stange J (2019). Multidimensional imaging techniques for prediction of treatment response in major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry, 91, 38-48.
  40. Kious BM, Bakian A, Zhao J, Mickey B, Guille C, Renshaw P, Sen (2019). Altitude and risk of depression and anxiety: findings from the intern health study. International review of psychiatry (Abingdon, England), 31(7-8), 637-645.
  41. Sankar A, Yttredahl AA, Fourcade EW, Mickey BJ, Love TM, Langenecker SA, Hsu D (2019). Dissociable Neural Responses to Monetary and Social Gain and Loss in Women With Major Depressive Disorder. Frontiers in behavioral neuroscience, 13, 149.
  42. Langenecker SA, Mickey BJ, Eichhammer P, Sen S, Elverman KH, Kennedy SE, Heitzeg MM, Ribeiro SM, Love TM, Hsu DT, Koeppe RA, Watson SJ, Akil H, Goldman D, Burmeister M, Zubieta J (2019). Cognitive Control as a 5-HT1A-Based Domain That Is Disrupted in Major Depressive Disorder. Frontiers in psychology, 10, 691.
  43. Yttredahl AA, McRobert E, Sheler B, Mickey BJ, Love TM, Langenecker SA, Zubieta JK, Hsu D (2018). Abnormal emotional and neural responses to romantic rejection and acceptance in depressed women. Journal of affective disorders, 234, 231-238.
  44. Mickey BJ, Ginsburg Y, Sitzmann AF, Grayhack C, Sen S, Kirschbaum C, Maixner DF, Abelson J (2018). Cortisol trajectory, melancholia, and response to electroconvulsive therapy. Journal of psychiatric research, 103, 46-53.
  45. Kang GE, Mickey BJ, McInnis MG, Krembs BS, Gross M (2018). Motor behavior characteristics in various phases of bipolar disorder revealed through biomechanical analysis: Quantitative measures of activity and energy variables during gait and sit-to-walk. Psychiatry research, 269, 93-101.
  46. Mickey BJ, White AT, Arp AM, Leonardi K, Torres MM, Larson AL, Odell DH, Whittingham SA, Beck MM, Jessop JE, Sakata DJ, Bushnell LA, Pierson MD, Solzbacher D, Kendrick EJ, Weeks HR 3rd, Light AR, Light KC, Tadler S (2018). Propofol for Treatment-Resistant Depression: A Pilot Study. The international journal of neuropsychopharmacology, 21(12), 1079-1089.
  47. Tadler SC, Mickey B (2018). Emerging evidence for antidepressant actions of anesthetic agents. Current opinion in anaesthesiology, 31(4), 439-445.
  48. Crane NA, Jenkins LM, Bhaumik R, Dion C, Gowins JR, Mickey BJ, Zubieta JK, Langenecker S (2017). Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain, 140(2), 472-486.
  49. Pecina M, Sikora M, Avery ET, Heffernan J, Pecina S, Mickey BJ, Zubieta J (2017). Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response. European neuropsychopharmacology, 27(10), 977-986.
  50. Jacobs RH, Barba A, Gowins JR, Klumpp H, Jenkins LM, Mickey BJ, Ajilore O, Pecina M, Sikora M, Ryan KA, Hsu DT, Welsh RC, Zubieta JK, Phan KL, Langenecker S (2016). Decoupling of the amygdala to other salience network regions in adolescent-onset recurrent major depressive disorder. Psychological medicine, 46(5), 1055-67.
  51. Mickey BJ, Heffernan J, Heisel C, Peciña M, Hsu DT, Zubieta JK, Love T (2016). Oxytocin modulates hemodynamic responses to monetary incentives in humans. Psychopharmacology, 233(23-24), 3905-3919.
  52. Gluskin BS, Mickey B (2016). Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies. Translational psychiatry, 6, e747.
  53. Sikora M, Heffernan J, Avery ET, Mickey BJ, Zubieta JK, Peciña (2016). Salience Network Functional Connectivity Predicts Placebo Effects in Major Depression. Biological psychiatry. Cognitive neuroscience and neuroimaging, 1(1), 68-76.
  54. Tadayonnejad R, Ajilore O, Mickey BJ, Crane NA, Hsu DT, Kumar A, Zubieta JK, Langenecker S (2016). Pharmacological modulation of pulvinar resting-state regional oscillations and network dynamics in major depression. Psychiatry research. Neuroimaging, 252, 10-18.
  55. Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey B (2015). Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. The Journal of clinical psychiatry, 76(10), 1374-84.
  56. DelDonno SR, Weldon AL, Crane NA, Passarotti AM, Pruitt PJ, Gabriel LB, Yau W, Meyers KK, Hsu DT, Taylor SF, Heitzeg MM, Herbener E, Shankman SA, Mickey BJ, Zubieta JK, Langenecker S (2015). Affective personality predictors of disrupted reward learning and pursuit in major depressive disorder. Psychiatry research, 230(1), 56-64.
  57. Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, Mickey BJ, Koeppe RA, Langenecker SA, Zubieta J (2015). It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Molecular psychiatry, 20(2), 193-200.
  58. Pecina M, Bohnert AS, Sikora M, Avery ET, Langenecker SA, Mickey BJ, Zubieta J (2015). Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression. JAMA psychiatry, 72(11), 1087-94.
  59. Glaser YG, Zubieta JK, Hsu DT, Villafuerte S, Mickey BJ, Trucco EM, Burmeister M, Zucker RA, Heitzeg M (2014). Indirect effect of corticotropin-releasing hormone receptor 1 gene variation on negative emotionality and alcohol use via right ventrolateral prefrontal cortex. The Journal of neuroscience, 34(11), 4099-107.
  60. Lohoff FW, Hodge R, Narasimhan S, Nall A, Ferraro TN, Mickey BJ, Heitzeg MM, Langenecker SA, Zubieta JK, Bogdan R, Nikolova YS, Drabant E, Hariri AR, Bevilacqua L, Goldman D, Doyle G (2014). Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Molecular psychiatry, 19(1), 129-39.
  61. Peciña M, Mickey BJ, Love T, Wang H, Langenecker SA, Hodgkinson C, Shen PH, Villafuerte S, Hsu D, Weisenbach SL, Stohler CS, Goldman D, Zubieta J (2013). DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience. Cortex; a journal devoted to the study of the nervous system and behavior, 49(3), 877-90.
  62. Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Wang H, Ni L, Walker SJ, Mickey BJ, Korycinski ST, Koeppe RA, Crocker JK, Langenecker SA, Zubieta J (2013). Response of the mu-opioid system to social rejection and acceptance. Molecular psychiatry, 18(11), 1211-7.
  63. Love TM, Enoch MA, Hodgkinson CA, Pecina M, Mickey B, Koeppe RA, Stohler CS, Goldman D, Zubieta JK (2012). Oxytocin gene polymorphisms influence human dopaminergic function in a sex-dependent manner. Biol Psychiatry, 72(3), 198-206.
  64. Hsu DT, Mickey BJ, Langenecker SA, Heitzeg MM, Love TM, Wang H, Kennedy SE, Peciña M, Shafir T, Hodgkinson CA, Enoch MA, Goldman D, Zubieta J (2012). Variation in the corticotropin-releasing hormone receptor 1 (CRHR1) gene influences fMRI signal responses during emotional stimulus processing. The Journal of neuroscience, 32(9), 3253-60.
  65. Mickey BJ, Sanford BJ, Love TM, Shen PH, Hodgkinson CA, Stohler CS, Goldman D, Zubieta J (2012). Striatal dopamine release and genetic variation of the serotonin 2C receptor in humans. The Journal of neuroscience, 32(27), 9344-50.
  66. Mickey BJ, Zhou Z, Heitzeg MM, Heinz E, Hodgkinson CA, Hsu DT, Langenecker SA, Love TM, Peciña M, Shafir T, Stohler CS, Goldman D, Zubieta JK (2011). Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry, 68(2), 158-66.
  67. Mickey BJ, Ducci F, Hodgkinson CA, Langenecker SA, Goldman D, Zubieta J (2008). Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. The Journal of neuroscience, 28(44), 11354-9.

Book Chapter

  1. Hristidis VC, Nagele P, Palanca BJ, Tadler SC, Mickey BJ, Gott BM, Conway C (2024). The Use of Inhaled Gases in Psychiatry. 383-401.
  2. Conway CR, Mickey BJ, Palanca BJ, Tadler SC, Nagele (2021). Inhaled Gases for Treatment-Resistant Major Depression. 481-491.
  3. Sen S, Mickey BJ, Greden J (2011). Psychopharmacological Roadmap for Treatment Resistant Depression. 33-49.

Commentary

  1. Mickey B (2016). Genetic variation and the D2 dopamine receptor: implications for the treatment of neuropsychiatric disease. Pharmacogenomics, 17(11), 1207-1210.

Case Report

  1. Campbell JM, Horn A, Kious BM, Rahimpour S, Mickey BJ, Shofty (2025). Tractography-guided DBS programming in treatment-resistant OCD: A case report and review of the literature. Biological psychiatry, in press,
  2. Jawish R, Smid M, Gordon A, Shangraw K, Mickey B (2024). Prolonged transcranial magnetic stimulation in a pregnant patient with treatment-resistant depression: a case report. Journal of medical case reports, 18(1), 512.
  3. Riis TS, Feldman DA, Vonesh LC, Brown JR, Solzbacher D, Kubanek J, Mickey B (2023). Durable effects of deep brain ultrasonic neuromodulation on major depression: a case report. Journal of medical case reports, 17(1), 449.
  4. Durns T, Rich B, Benson C, Mickey BJ, Weischedel (2020). A Case of biopharmaceutical-induced catatonia and the implication of a novel mechanism. The journal of ECT, 36(3), e29.

Research Lab

Lab link